Jasper Therapeutics Inc. (JSPR)
NASDAQ: JSPRHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
JSPR stock chart
Technical analysisKey statistics
All statistics- Market cap
- $18.63M
- EPS (TTM)
- -$1.04
- Dividend yield
- None
- 52-week range
- 0.315 – 2.69
- Day range
- 0.5405 – 0.58
- Volume / Avg
- 362.25K / 1.37M
- Beta
- —
- Shares outstanding
- 33.27M
52-week range
JSPR stock today
Jasper Therapeutics (JSPR) closed at $0.56 on Oct 8, down 1.70% (-$0.0097), versus the S&P 500's 0.47% decline. Trading was light, with 362.25K shares changing hands, about 27% of the average daily volume. Shares are 79.2% below their 52-week high of $2.69, set on Oct 20, 2025 and 77.8% above the 52-week low of $0.315, near the bottom of the past year's range.
JSPR is down 69.4% year to date, underperforming the S&P 500 (+13.5%). Over the past 12 months, the stock has lost 76.7%. Jasper Therapeutics has posted a net loss over the last twelve months (EPS of -$1.04), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Jasper Therapeutics
Company profileJasper Therapeutics, Inc., a clinical stage biotechnology company, focuses on the design and development of therapies to treat immune-mediated diseases. It is advancing a pipeline of medicines, including KP-104, a dual-complement inhibitor that has demonstrated positive outcomes in paroxysmal nocturnal hemoglobinuria (PNH) and is under evaluation in other unmet need nephrology disorders; Briquilimab is an anti-KIT antibody, which has demonstrated clinical results as a conditioning agent for stem cell transplant and mast cell mediated diseases, such as chronic urticarias and allergic asthma; and KP-701, a novel, dual-acting anti-CD79BxCD32B monoclonal antibody (mAb) for autoantibody-mediated disorders. The company is based in Redwood City, California.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Headquarters
- Redwood City, CA
- IPO year
- 2020
- Website
- jaspertx.com
Analyst forecast
ForecastConsensus (1 analysts)
none
Avg. price target
$20.00+3471.43%
- Strong buy 0
- Buy 1
- Hold 0
- Sell 0
- Strong sell 0
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Jasper Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ESLAEstrella Immunopharma Inc. | 0.4175 | -0.43% | $18.16M | vs JSPR |
| DYAIDyadic International Inc. | 0.4444 | -2.65% | $17.80M | vs JSPR |
| SCLXScilex Holding Company | 2.96 | -15.19% | $20.82M | vs JSPR |
| BCDABioCardia Inc. | 1.06 | -2.75% | $16.05M | vs JSPR |
| TCRXTScan Therapeutics Inc. | 0.2282 | -17.59% | $15.47M | vs JSPR |
| INABIN8bio Inc. | 1.38 | -1.43% | $13.60M | vs JSPR |
| ATYRaTyr Pharma Inc. | 0.2553 | -8.26% | $25.04M | vs JSPR |
| PLURPluri Inc. | 1.00 | -3.85% | $12.61M | vs JSPR |
Indexes, lists and sector
Jasper Therapeutics stock FAQ
What is Jasper Therapeutics's stock price today?
JSPR last traded at $0.56 as of Oct 8, 4:00 PM EDT, down 1.70% on the day. Prices are delayed at least 15 minutes.
Does Jasper Therapeutics pay a dividend?
No. Jasper Therapeutics does not currently pay a regular cash dividend.
Has JSPR ever split its stock?
Yes. The most recent JSPR stock split was a 1-for-10 split on Jan 4, 2024.
What is the JSPR 52-week high?
The 52-week high for JSPR is $2.69 and the 52-week low is $0.315. The stock is currently 79.2% below its high.